Edwards Lifesciences (EW) Stock Forecast & Price Target $85.93 +2.73 (+3.28%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$85.21 -0.72 (-0.84%) As of 05/22/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 28 Analyst RatingsSell0Hold9Buy19 Based on 28 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 28 analysts, 9 have given a hold rating, 16 have given a buy rating, and 3 have given a strong buy rating for EW. Consensus Price Target $95.6511.31% Upside According to the 28 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $95.65. The highest price target for EW is $110.00, while the lowest price target for EW is $81.00. The average price target represents a forecasted upside of 11.31% from the current price of $85.93. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for EW and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EW Analyst Ratings Over TimeTypeCurrent Forecast5/24/25 to 5/24/261 Month Ago4/24/25 to 4/24/263 Months Ago2/23/25 to 2/23/261 Year Ago5/24/24 to 5/24/25Strong Buy3 Strong Buy rating(s)3 Strong Buy rating(s)3 Strong Buy rating(s)0 Strong Buy rating(s)Buy16 Buy rating(s)16 Buy rating(s)15 Buy rating(s)10 Buy rating(s)Hold9 Hold rating(s)9 Hold rating(s)9 Hold rating(s)11 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)1 Sell rating(s)Consensus Price Target$95.65$95.48$96.14$80.20Forecasted Upside11.31% Upside13.39% Upside16.47% Upside6.96% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyHold EW Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History EW Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Edwards Lifesciences Stock vs. The CompetitionTypeEdwards LifesciencesMedical CompaniesBroader MarketConsensus Rating Score 2.79 2.30 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside11.31% Upside1,714.95% Upside15.09% UpsideNews Sentiment RatingPositive NewsSee Recent EW NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails4/27/2026 Barclays3 of 5 starsMatt Miksic2 of 5 starsReiterated RatingOverweight$104.00 ➝ $110.00+30.64%4/24/2026 Truist Financial3 of 5 starsRichard Newitter2 of 5 starsSet TargetHold$89.00 ➝ $90.00+8.03%4/24/2026 Evercore3 of 5 stars Reiterated RatingOutperform$93.00+11.71%4/24/2026 Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingWilliam PlovanicSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetHold$87.00 ➝ $85.00+2.10%4/24/2026 Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid RescottSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$85.00 ➝ $87.00+9.17%4/24/2026 BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMarie ThibaultSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$98.00 ➝ $100.00+25.48%4/20/2026 Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingHold (C)4/13/2026 MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAnthony PetroneSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetOutperform$100.00 ➝ $95.00+22.95%4/1/2026 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradePeer Perform ➝ Outperform$92.00+14.91%2/11/2026 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid RomanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$108.00 ➝ $95.00+23.38%The SpaceX filing is public. The window is closing. (Ad)SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the largest in history. The 21-bank syndicate has already locked up shares, so retail investors won't get access. But the S-1 exposed one publicly traded company Musk cannot operate without - and it's still cheap. Dylan Jovine is releasing the ticker free before June 12 changes the price.Get the ticker before the SpaceX IPO reprices everything on June 122/11/2026 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAdam MaederSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight$98.00 ➝ $100.00+29.87%2/11/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLarry BiegelsenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$96.00 ➝ $100.00+31.67%2/4/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDanielle AntalffySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingNeutral$94.00+14.94%1/20/2026 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRick WiseSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetBuy$105.00 ➝ $110.00+30.35%1/9/2026 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeHold ➝ Buy12/18/2025 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRobbie MarcusSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$90.00 ➝ $100.00+17.85%12/11/2025 CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoanne WuenschSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$96.00 ➝ $101.00+20.29%12/5/2025 Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingShagun SinghSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$95.00 ➝ $100.00+15.60%11/3/2025 Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLee HambrightSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingMarket Perform$90.00+9.12%11/3/2025 Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJayson BedfordSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$96.00+16.39%10/31/2025 National Bank FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$92.00+11.54%10/29/2025 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatthew TaylorSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetHold ➝ Buy$80.00 ➝ $98.00+19.14%10/8/2025 OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSuraj KaliaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/29/2025 Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeHold ➝ Strong-Buy7/25/2025 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong-Buy7/25/2025 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingPito ChickeringSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$85.00 ➝ $94.00+24.21%7/15/2025 Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingPatrick WoodSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetEqual Weight$75.00 ➝ $81.00+3.39%7/10/2025 ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingChristine DooleySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy6/2/2025 Dbs BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingN. ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeHold12/16/2024 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeNeutral ➝ Buy$82.00 ➝ $90.00+20.97%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:34 PM ET. Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, May 17, 2026. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com. Edwards Lifesciences Bull Case Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.: The current stock price is around $82, reflecting a stable position in the market. Edwards Lifesciences Co. reported a significant revenue increase of 16.7% compared to the same quarter last year, indicating strong growth potential. The company has a solid net margin of 17.39%, showcasing effective cost management and profitability. With a low debt-to-equity ratio of 0.06, Edwards Lifesciences Co. demonstrates a strong balance sheet and financial stability, which is attractive to investors. The company has set ambitious earnings per share (EPS) guidance for FY 2026, indicating confidence in future performance. Edwards Lifesciences Bear Case Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons: The price-to-earnings (PE) ratio of 44.72 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors. Insider selling activity has been notable, with significant shares sold recently, which may raise concerns about the company's future prospects. The beta of 0.87 indicates that the stock is less volatile than the market, which might not appeal to investors seeking high-risk, high-reward opportunities. Despite strong revenue growth, the price-to-earnings-growth (PEG) ratio of 2.11 suggests that the stock's growth may not justify its current price, indicating potential overvaluation. Corporate insiders own only 0.31% of the company's stock, which may signal a lack of confidence in the company's future from those closest to its operations. EW Forecast - Frequently Asked Questions What is Edwards Lifesciences' forecast for 2026? According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $95.65, with a high forecast of $110.00 and a low forecast of $81.00. Should I buy or sell Edwards Lifesciences stock right now? 28 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 9 hold ratings, 16 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EW shares. Does Edwards Lifesciences's stock price have much upside? According to analysts, Edwards Lifesciences's stock has a predicted upside of 11.31% based on their 12-month stock forecasts. Has Edwards Lifesciences been upgraded by Wall Street analysts recently? Over the previous 90 days, Edwards Lifesciences's stock had 1 upgrade by analysts. What analysts cover Edwards Lifesciences? Edwards Lifesciences has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Evercore, Mizuho, Robert W. Baird, Truist Financial, Weiss Ratings, and Wolfe Research in the past 90 days. Do Wall Street analysts like Edwards Lifesciences more than its competitors? Analysts like Edwards Lifesciences more than other "medical" companies. The consensus rating for Edwards Lifesciences is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how EW compares to other companies. Stock Forecasts and Research Tools Related Companies HSIC Stock Forecast AMN Stock Forecast ISRG Stock Forecast ABT Stock Forecast SYK Stock Forecast MDT Stock Forecast BSX Stock Forecast IDXX Stock Forecast BDX Stock Forecast RMD Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Edwards Lifesciences RecommendationsBarclaysTruist FinancialEvercoreCanaccord Genuity GroupRobert W. BairdBTIG ResearchWeiss RatingsMizuhoWolfe ResearchWells Fargo & CompanyThe Goldman Sachs GroupPiper SandlerUBS GroupStifel NicolausTD Cowen This page (NYSE:EW) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
